Armin Ghobadi – författare

Focusing on the essential information you need to know for the clinical practice of oncology, this practical volume in the Lippincott Manual series provides concise, high-yield content that reflects today’s fast-changing advances in the field. In one convenient, portable resource, you’ll find complete coverage of cancer management, all at your fingertips for quick review and reference. The Washington Manual® of Oncology, 4th Edition, by Drs. Daniel Morgensztern, Armin Ghobadi, and Ramaswamy Govindan, is an ideal reference for oncologists, residents, fellows, medical students, nurse practitioners, and physician assistants. , The latest, most reliable cancer management recommendations in the famous fast-access Washington Manual® outline format that includes easy-to-follow guidelines, tables, graphs, and algorithms. Thoroughly revised from cover to cover, including new content on gene and cellular immunotherapy for cancer, management of antineoplastic-induced nausea and vomiting as well as new sections on neuroendocrine carcinoma and myelodysplastic syndromes. Concise, clearly written sections on the principles of oncology, site-specific cancers, and therapy and support. Key information on chemotherapeutic agents and regimens in the appendices.   The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by WoltersKluwer Health under license from Washington University. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more.  Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more.  Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.